How Diversity In Therapeutic Strategies Is Expanding The Drug Discovery Toolbox

Bifunctional Molecules: A Diverse New Modality That Unlocks New Target Classes

CRISPR Library Screen: A Powerful Tool For Identifying Novel Tumor Targets

CRISPR Cas9 library screen in primary T cells diffuse large B cell lymphoma cells to identify modulators in tumor-immune interaction

Inflammasome Activation in M2 Macrophage Restrain the Immune Supperssive Function

Validation of the Combinatorial Effect of Blinatumomab and Nivolumab in Caner Therapy

Enabling Technology for Targeted Protein Degradation

Unlocking the potential of DEL | Inspire Hit Discovery

Interview of Dr. Xuanjia Peng

Faster with high-speed fragment screening —Accelerate your drug discovery campaign

Magical Power of QM

To Empower Organic Syntheses

Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond

Interview of Dr. Phil Jones, VP of Therapeutics Discovery

Specialty Chemistry Platform and Capabilities at WuXi AppTec RSD

Cutting-edge synthetic technology and expertise in special chemical matters

Merging a Passion for Biochemistry, Synthetic Chemistry, and Bioactive Molecules in Academia

Interview of Dr. Joseph Ready, Co-Founder, Rodeo

In vivo CRISPR Animal Models 

High efficiency genome editing service for drug discovery

Empowering Chemistry with Quantum Mechanics

WuXi’s RSD teams are applying and developing QM calculations in multiple areas for organic syntheses

Shifting the Paradigm of Resistance and Undruggables for Unmet Medical Needs in Cancer, Neuroscience, and Beyond

Interview of John Houston, Arvinas

DELopen: DNA Encoded Library (DEL) Platform Offering more than 2.8 Billion Compounds

Apply for DNA-Encoded Library compound for free

OncoWuXi Database: To Facilitate Oncology Drug Discovery and Translational Oncology

Providing a portable oncology database for selection and inquiry of 1,000+ models for cancer research

DELopen Promotes Worldwide Academic Research Using DNA-Encoded Libraries, Far More Than Just a Numbers Game

Interview of Dr. Richard Lerner